Point72 Asset Management’s Ventyx Biosciences VTYX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-1,056,520
| Closed | -$9.54M | – | 4573 |
|
|
2025
Q4 | $9.54M | Sell |
1,056,520
-2,153,125
| -67% | -$16.1M | 0.01% | 1381 |
|
|
2025
Q3 | $9.98M | Sell |
3,209,645
-2,685,424
| -46% | -$7.11M | 0.02% | 796 |
|
|
2025
Q2 | $12.6M | Buy |
5,895,069
+1,660,265
| +39% | +$2.68M | 0.02% | 648 |
|
|
2025
Q1 | $4.87M | Buy |
4,234,804
+2,452,797
| +138% | +$4.21M | 0.01% | 937 |
|
|
2024
Q4 | $3.9M | Buy |
+1,782,007
| New | +$4.04M | 0.01% | 1028 |
|
|
2024
Q2 | – | Sell |
-2,531,002
| Closed | -$13.9M | – | 2501 |
|
|
2024
Q1 | $13.9M | Buy |
+2,531,002
| New | +$11.6M | 0.03% | 593 |
|
|
2023
Q4 | – | Sell |
-1,298,493
| Closed | -$45.1M | – | 2888 |
|
|
2023
Q3 | $45.1M | Buy |
1,298,493
+499,493
| +63% | +$17.3M | 0.13% | 194 |
|
|
2023
Q2 | $26.2M | Sell |
799,000
-270,400
| -25% | -$9.32M | 0.08% | 319 |
|
|
2023
Q1 | $35.8M | Buy |
1,069,400
+690,100
| +182% | +$26.8M | 0.11% | 225 |
|
|
2022
Q4 | $12.4M | Buy |
+379,300
| New | +$11.2M | 0.04% | 482 |
|
|
2022
Q3 | – | Sell |
-206,400
| Closed | -$2.52M | – | 1762 |
|
|
2022
Q2 | $2.52M | Sell |
206,400
-19,900
| -9% | -$297K | 0.01% | 886 |
|
|
2022
Q1 | $3.07M | Buy |
+226,300
| New | +$3.02M | 0.01% | 802 |
|
Other funds holding VTYX
Point72 Asset Management's VTYX Position: Q1 2026 in Review
Point72 Asset Management sold out of Ventyx Biosciences (VTYX) in Q1 2026, closing a stake of 1,056,520 shares — an estimated $9.54M sold.
Point72 Asset Management first reported a position in VTYX in Q1 2022 and held it in 12 quarters. The position peaked at $45.1M in Q3 2023. 1 fund tracked by Wall St. Rank holds VTYX as of Q1 2026.
- Point72 Asset Management reported no remaining Ventyx Biosciences position as of Q1 2026 after selling out during the quarter.
- Point72 Asset Management sold 1,056,520 Ventyx Biosciences shares in Q1 2026, an estimated $9.54M.
- Point72 Asset Management first reported a position in Ventyx Biosciences in Q1 2022 and held it in 12 quarters.
- Point72 Asset Management's Ventyx Biosciences position peaked at $45.1M in Q3 2023.
- 1 fund tracked by Wall St. Rank held Ventyx Biosciences as of Q1 2026.
Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.